Aurinia Q2 Revenue $83.2M (+19%), EPS $0.28 (+75%)
Aurinia Pharmaceuticals reported strong financial results for Q2 2026, with total revenue increasing 19% to $83.2 million and diluted earnings per share rising 75% to $0.28. Net product sales of LUPKYNIS grew 19% to $79.4 million. The company ended the quarter with $443.1 million in cash and investments and reiterated its 2026 revenue guidance of $315 million to $325 million. Aurinia also provided updates on its clinical pipeline, including the initiation of a Phase 4 study for LUPKYNIS and clinical development for Aritinercept in four indications.
Key Highlights
- Q2 2026 Total Revenue increased 19% to $83.2 million.
- Q2 2026 Net Product Sales of LUPKYNIS rose 19% to $79.4 million.
- Q2 2026 Diluted EPS grew 75% to $0.28.
- Cash, cash equivalents, and investments totaled $443.1 million as of June 30, 2026.
- Reiterated 2026 total revenue guidance of $315 million to $325 million.
- Initiated PRESERVE, a Phase 4 study for LUPKYNIS in lupus nephritis.
- Initiated clinical development of Aritinercept in four potential indications.
Price Impact
More from AUPH
Aurinia Q2 Revenue $83.2M, Net Income $37.4M; Acquires Kezar
Aurinia Pharmaceuticals Inc. Shareholders Elect Board, Approve Auditor and Executive Compensation
Aurinia Completes Kezar Life Sciences Acquisition for $6.955/Share